| Dr Eric Kent Cannon, MD | |
|
1034 N 500 W, Provo, UT 84604-3380 | |
| (801) 357-7850 | |
| Not Available |
| Full Name | Dr Eric Kent Cannon |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 15 Years |
| Location | 1034 N 500 W, Provo, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134362304 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 53292 (Minnesota) | Secondary |
| 207L00000X | Anesthesiology | 8622599-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Utah Valley Hospital | Provo, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mountain West Anesthesia Llc | 9032018502 | 248 |
News Archive
Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology.
The influenza pandemic has gathered a lot of action, advice and coverage over the last few years. In 2009, an international H1N1 influenza pandemic led to concerns that there would be a repeat of the 1918 influenza pandemic which resulted in millions of deaths worldwide. The World Health Organization recorded over 37,000 cases of the H1N1 pandemic influenza in Australia and 193 confirmed deaths.
Johns Hopkins scientists have discovered a protein that appears to play an important regulatory role in deciding whether stem cells differentiate into the cells that make up the brain, as well as countless other tissues.
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
› Verified 5 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology.
The influenza pandemic has gathered a lot of action, advice and coverage over the last few years. In 2009, an international H1N1 influenza pandemic led to concerns that there would be a repeat of the 1918 influenza pandemic which resulted in millions of deaths worldwide. The World Health Organization recorded over 37,000 cases of the H1N1 pandemic influenza in Australia and 193 confirmed deaths.
Johns Hopkins scientists have discovered a protein that appears to play an important regulatory role in deciding whether stem cells differentiate into the cells that make up the brain, as well as countless other tissues.
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
› Verified 5 days ago
| Entity Name | Mountain West Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558391763 PECOS PAC ID: 9032018502 Enrollment ID: O20040103000057 |
News Archive
Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology.
The influenza pandemic has gathered a lot of action, advice and coverage over the last few years. In 2009, an international H1N1 influenza pandemic led to concerns that there would be a repeat of the 1918 influenza pandemic which resulted in millions of deaths worldwide. The World Health Organization recorded over 37,000 cases of the H1N1 pandemic influenza in Australia and 193 confirmed deaths.
Johns Hopkins scientists have discovered a protein that appears to play an important regulatory role in deciding whether stem cells differentiate into the cells that make up the brain, as well as countless other tissues.
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eric Kent Cannon, MD Po Box 3570, Salt Lake City, UT 84110-3570 Ph: (801) 727-2056 | Dr Eric Kent Cannon, MD 1034 N 500 W, Provo, UT 84604-3380 Ph: (801) 357-7850 |
News Archive
Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology.
The influenza pandemic has gathered a lot of action, advice and coverage over the last few years. In 2009, an international H1N1 influenza pandemic led to concerns that there would be a repeat of the 1918 influenza pandemic which resulted in millions of deaths worldwide. The World Health Organization recorded over 37,000 cases of the H1N1 pandemic influenza in Australia and 193 confirmed deaths.
Johns Hopkins scientists have discovered a protein that appears to play an important regulatory role in deciding whether stem cells differentiate into the cells that make up the brain, as well as countless other tissues.
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
› Verified 5 days ago
Dr. Daniel Rey Faber, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 280 River Park Dr, #200, Provo, UT 84604 Phone: 801-223-4860 Fax: 801-371-8993 | |
John B Zimmerman, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1034 North 500 West, Utah Valley Regional Medical Center, Provo, UT 84604 Phone: 801-507-5248 Fax: 801-733-5618 | |
David Groesbeck, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1034 North 500 West, Utah Valley Regional Medical Center, Provo, UT 84604 Phone: 801-507-5248 Fax: 801-733-5618 | |
Carl Thayne Wilson, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1034 North 500 West, Utah Valley Regional Medical Center, Provo, UT 84604 Phone: 801-507-5248 Fax: 801-733-5618 | |
Mr. Matthew David Wagaman, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-7850 Fax: 770-701-6675 | |
Mitchell D Albrecht, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1034 N 500 W, Provo, UT 84004 Phone: 801-993-9582 Fax: 801-733-5618 | |
Mark Critchfield, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1034 North 500 West, Utah Valley Regional Medical Center, Provo, UT 84604 Phone: 801-507-5248 Fax: 801-733-5618 |